Metabolic syndrome, abdominal obesity and hyperuricemia in schizophrenia: Results from the FACE-SZ cohort

Schizophrenia Research

Volumn 168, Issue 1-2, 2015, Pages 388-394

  Godin, O ^a,b,c   Leboyer, M ^a,d   Gaman, A ^a   Aouizerate, B ^a,e,f,p   Berna, F ^a,g   Brunel, L ^a,d   Capdevielle, D ^a,h   Chereau, I ^a,i   Dorey, J M ^a,j   Dubertret, C ^a,k   Dubreucq, J ^a,l   Faget, C ^a,m   Gabayet, F ^a,l   Le Strat, Y ^a,k   Llorca, P M ^a,i   Misdrahi, D ^a,e,f,q   Rey, R ^a,j   Richieri, R ^a,m   Passerieux, C ^a,n,r   Schandrin, A ^a,h   Schurhoff F ^a,d   Urbach, M ^a,n,r   Vidalhet, P ^g   Girerd, N ^o   Fond, G ^a,a,d,d   Blanc, O ^a,i   Bulzacka, E ^a,d   Chereau Boudet, I ^a,i   Chesnoy Servanin, G ^a,j   Danion, J M ^a,g   D'Amato, T ^a,j   Deloge, A ^a,e,f   Delorme, C ^a,l   Denizot, H ^a,i   Depradier, M ^a,k   Fluttaz, C ^a,l   Fonteneau, S ^a,r   Giraud Baro, E ^a,l   Hardy Bayle, M C ^a,r   Lacelle, D ^a,i   Lancon C ^a,m   Laouamri, H ⁿ   Le Gloahec, T ^a,d   Metairie, E ^a,m   Offerlin Meyer, I ^a,g   Peri, P ^a,m   Pires, S ^a,i   Portalier, C ^a,k   Roman, C ^a,l   Sebilleau, M ^a,r   Tessier, A ^a,e,f   Tronche, A M ^a,i   Vaillant, F ^a,m   Vehier, A ^a,j   Vidailhet, P ^a,g   Vila E ^a,e,f   Yazbek, H ^a,h   Zinetti Bertschy, A ^a,g   more..

^a FONDATION FONDAMENTAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSTITUT PIERRE LOUIS D EPIDÉMIOLOGIE ET DE SANTÉ PUBLIQUE   (France)

^d INSERM U955   (France)

^e CENTRE HOSPITALIER CHARLES PERRENS   (France)

^f UNIVERSITÉ DE BORDEAUX   (France)

^g UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^h MONTPELLIER UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^j UNIVERSITÉ LYON 1   (France)

^k INSERM   (France)

^l C3R Grenoble   (France)

^m ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

ⁿ LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^o UNIVERSITÉ DE LORRAINE   (France)

^p INSTITUT FRANÇOIS MAGENDIE   (France)

^q CNRS   (France)

^r CENTRE HOSPITALIER DE VERSAILLES   (France)

more..

Author keywords

Abdominal obesity; Comorbidity; Hyperuricemia; Metabolic syndrome; Schizophrenia

Indexed keywords

CLOZAPINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; URIC ACID; HIGH DENSITY LIPOPROTEIN;

ABDOMINAL OBESITY; ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; DIETARY INTAKE; DISEASE ASSOCIATION; DYSLIPIDEMIA; EDUCATIONAL STATUS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC STRESS; METABOLIC SYNDROME X; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; URIC ACID BLOOD LEVEL; WAIST CIRCUMFERENCE; ANTHROPOMETRY; BLOOD; BLOOD PRESSURE; BODY MASS; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COHORT ANALYSIS; FRANCE; METABOLIC DISEASES; MULTICENTER STUDY; OBESITY, ABDOMINAL; PHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; YOUNG ADULT;

ADULT; ANTHROPOMETRY; BLOOD PRESSURE; BODY MASS INDEX; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; FEMALE; FRANCE; HUMANS; HYPERURICEMIA; LIPOPROTEINS, HDL; MALE; METABOLIC DISEASES; OBESITY, ABDOMINAL; PREVALENCE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84942369645     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.07.047     Document Type: Article

References (46)

1. Abel K.M., Drake R., Goldstein J.M. Sex differences in schizophrenia. Int. Rev. Psychiatry 2010, 22(5):417-428.
2. Addington D., Addington J., Maticka-Tyndale E. Rating depression in schizophrenia. A comparison of a self-report and an observer report scale. J. Nerv. Ment. Dis. 1993, 181(9):561-565.
3. Alberti K.G., Zimmet P., Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet. Med. 2006, 23(5):469-480.
4. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., Weiden P.J. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 1999, 156(11):1686-1696.
5. Aribas A., Kayrak M., Ulucan S., Keser A., Demir K., Alibasic H., Akilli H., Solak Y., Avci A., Turan Y., Kaya Z., Katlandur H., Kanbay M. The relationship between uric acid and erectile dysfunction in hypertensive subjects. Blood Press. 2014, 23(6):370-376.
6. Balkau B., Vernay M., Mhamdi L., Novak M., Arondel D., Vol S., Tichet J., Eschwege E., Group D.E.S.I.R.S. The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.I.R. study. Diabetes Metab. 2003, 29(5):526-532.
7. Bobes J., Arango C., Garcia-Garcia M., Rejas J. Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophr. Res. 2010, 119(1-3):101-109.
8. Chen J.H., Chuang S.Y., Chen H.J., Yeh W.T., Pan W.H. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum. 2009, 61(2):225-232.
9. Chiu C.C., Chen C.H., Huang M.C., Chen P.Y., Tsai C.J., Lu M.L. The relationship between serum uric acid concentration and metabolic syndrome in patients with schizophrenia or schizoaffective disorder. J. Clin. Psychopharmacol. 2012, 32(5):585-592.
10. De Hert M., Mauri M., Shaw K., Wetterling T., Doble A., Giudicelli A., Falissard B. The METEOR study of diabetes and other metabolic disorders in patients with schizophrenia treated with antipsychotic drugs. I. Methodology. Int. J. Methods Psychiatr. Res. 2010, 19(4):195-210.
11. Despres J.P., Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006, 444(7121):881-887.
12. Girerd N., Pibarot P., Fournier D., Daleau P., Voisine P., O'Hara G., Després J.P., Mathieu P. Middle-aged men with increased waist circumference and elevated C-reactive protein level are at higher risk for postoperative atrial fibrillation following coronary artery bypass grafting surgery. Eur. Heart. J. 2009, 30(10):1270-1278. (May). 10.1093/eurheartj/ehp091.
13. Godin O., Etain B., Henry C., Bougerol T., Courtet P., Mayliss L., Passerieux C., Azorin J.M., Kahn J.P., Gard S., Costagliola D., Leboyer M., FondaMental Advanced Centers of Expertise in Bipolar Disorders C. Metabolic syndrome in a French cohort of patients with bipolar disorder: results from the FACE-BD cohort. J. Clin. Psychiatry 2014, 75(10):1078-1085.
14. Han G.M., Gonzalez S., DeVries D. Combined effect of hyperuricemia and overweight/obesity on the prevalence of hypertension among US adults: result from the National Health and Nutrition Examination Survey. J. Hum. Hypertens. 2014, 28(10):579-586.
15. Huang Y., Li Y.L., Huang H., Wang L., Yuan W.M., Li J. Effects of hyperuricemia on renal function of renal transplant recipients: a systematic review and meta-analysis of cohort studies. PLoS One 2012, 7(6):e39457.
16. Ishizaka Y., Yamakado M., Toda A., Tani M., Ishizaka N. Relationship between serum uric acid and serum oxidative stress markers in the Japanese general population. Nephron Clin. Pract. 2014, 128(1-2):49-56. 10.1159/000362456.
17. Khanna D., Fitzgerald J.D., Khanna P.P., Bae S., Singh M.K., Neogi T., Pillinger M.H., Merill J., Lee S., Prakash S., Kaldas M., Gogia M., Perez-Ruiz F., Taylor W., Liote F., Choi H., Singh J.A., Dalbeth N., Kaplan S., Niyyar V., Jones D., Yarows S.A., Roessler B., Kerr G., King C., Levy G., Furst D.E., Edwards N.L., Mandell B., Schumacher H.R., Robbins M., Wenger N., Terkeltaub R., American College of R 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012, 64(10):1431-1446.
18. Khanna D., Khanna P.P., Fitzgerald J.D., Singh M.K., Bae S., Neogi T., Pillinger M.H., Merill J., Lee S., Prakash S., Kaldas M., Gogia M., Perez-Ruiz F., Taylor W., Liote F., Choi H., Singh J.A., Dalbeth N., Kaplan S., Niyyar V., Jones D., Yarows S.A., Roessler B., Kerr G., King C., Levy G., Furst D.E., Edwards N.L., Mandell B., Schumacher H.R., Robbins M., Wenger N., Terkeltaub R., American College of R 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012, 64(10):1447-1461.
19. Kim S.Y., Guevara J.P., Kim K.M., Choi H.K., Heitjan D.F., Albert D.A. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum. 2009, 61(7):885-892.
20. Kim S.Y., Guevara J.P., Kim K.M., Choi H.K., Heitjan D.F., Albert D.A. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res. 2010, 62(2):170-180.
21. Leucht S., Arbter D., Engel R.R., Kissling W., Davis J.M. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol. Psychiatry 2009, 14(4):429-447.
22. Li L., Yang C., Zhao Y., Zeng X., Liu F., Fu P. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: a systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 2014, 15:122.
23. Lin W.Y., Liu C.S., Li T.C., Lin T., Chen W., Chen C.C., Li C.I., Lin C.C. In addition to insulin resistance and obesity, hyperuricemia is strongly associated with metabolic syndrome using different definitions in Chinese populations: a population-based study (Taichung Community Health Study). Ann. Rheum. Dis. 2008, 67(3):432-433.
24. Liu W.C., Hung C.C., Chen S.C., Yeh S.M., Lin M.Y., Chiu Y.W., Kuo M.C., Chang J.M., Hwang S.J., Chen H.C. Association of hyperuricemia with renal outcomes, cardiovascular disease, and mortality. Clin. J. Am. Soc. Nephrol. 2012, 7(4):541-548.
25. Ma X., Maimaitirexiati T., Zhang R., Gui X., Zhang W., Xu G., Hu G. HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis. Int. J. Psychiatry Clin. Pract. 2014, 18(4):229-242.
26. Matsuura F., Yamashita S., Nakamura T., Nishida M., Nozaki S., Funahashi T., Matsuzawa Y. Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. Metab. Clin. Exp. 1998, 47(8):929-933.
27. Martínez-St John D.R., Palazón-Bru A., Gil-Guillén V.F., Sepehri A., Navarro-Cremades F., Ramírez-Prado D., Orozco-Beltrán D., Carratalá-Munuera C., Cortés E., Rizo-Baeza M.M. Diagnostic inertia in obesity and the impact on cardiovascular risk in primary care: a cross-sectional study. Br. J. Gen. Pract. 2015, 65(636):e454-e459. (Jul). 10.3399/bjgp15X685669.
28. McClave A.K., McKnight-Eily L.R., Davis S.P., Dube S.R. Smoking characteristics of adults with selected lifetime mental illnesses: results from the 2007 National Health Interview Survey. Am. J. Public Health 2010, 100(12):2464-2472.
29. McGrath J., Saha S., Welham J., El Saadi O., MacCauley C., Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med. 2004, 2:13.
30. Mitchell A.J., Delaffon V., Vancampfort D., Correll C.U., De Hert M. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol. Med. 2012, 42(1):125-147.
31. Mitchell A.J., Vancampfort D., De Herdt A., Yu W., De Hert M. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr. Bull. 2013, 39(2):295-305.
32. Mitchell A.J., Vancampfort D., Sweers K., van Winkel R., Yu W., De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and meta-analysis. Schizophr. Bull. 2013, 39(2):306-318.
33. Newcomer J.W. Antipsychotic medications: metabolic and cardiovascular risk. J. Clin. Psychiatry 2007, 68(Suppl. 4):8-13.
34. Niskanen L.K., Laaksonen D.E., Nyyssonen K., Alfthan G., Lakka H.M., Lakka T.A., Salonen J.T. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch. Intern. Med. 2004, 164(14):1546-1551.
35. Pannier B., Thomas F., Eschwege E., Bean K., Benetos A., Leocmach Y., Danchin N., Guize L. Cardiovascular risk markers associated with the metabolic syndrome in a large French population: the "SYMFONIE" study. Diabetes Metab. 2006, 32(5 Pt 1):467-474.
36. Park S.H., Shin W.Y., Lee E.Y., Gil H.W., Lee S.W., Lee S.J., Jin D.K., Hong S.Y. The impact of hyperuricemia on in-hospital mortality and incidence of acute kidney injury in patients undergoing percutaneous coronary intervention. Circ. J. 2011, 75(3):692-697.
37. Pingmuangkaew P., Tangvarasittichai O., Tangvarasittichai S. Association of Elevated Serum Uric Acid with the Components of Metabolic Syndrome and Oxidative Stress in Abdominal Obesity Subjects. Indian J. Clin. Biochem. 2015, 30(3):286-292. (Jul). 10.1007/s12291-014-0462-0.
38. Reininghaus U., Dutta R., Dazzan P., Doody G.A., Fearon P., Lappin J., Heslin M., Onyejiaka A., Donoghue K., Lomas B., Kirkbride J.B., Murray R.M., Croudace T., Morgan C., Jones P.B. Mortality in schizophrenia and other psychoses: a 10-year follow-up of the SOP first-episode cohort. Schizophr. Bull. 2014.
39. Schürhoff F., Fond G., Berna F., Bulzacka E., Vilain J., Capdevielle D., Misdrahi D., Leboyer M., Llorca P.M. FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) collaborators. A National network of schizophrenia expert centres: An innovative tool to bridge the research-practice gap. Eur Psychiatry 2015, (Jun 10, Epub ahead of print). 10.1016/j.eurpsy.2015.05.004.
40. Shiraishi H., Une H. The effect of the interaction between obesity and drinking on hyperuricemia in Japanese male office workers. J. Epidemiol. 2009, 19(1):12-16.
41. Vancampfort D., Wampers M., Mitchell A.J., Correll C.U., De Herdt A., Probst M., De Hert M. A meta-analysis of cardio-metabolic abnormalities in drug naive, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry 2013, 12(3):240-250.
42. Viazzi F., Leoncini G., Pontremoli R. Cardiovascular and renal effects of hyperuricaemia and gout. Reumatismo 2011, 63(4):253-262.
43. WHO WHO Mortality Database: Description and Sources of Data 2014.
44. Xu Y., Zhu J., Gao L., Liu Y., Shen J., Shen C., Matfin G., Wu X. Hyperuricemia as an independent predictor of vascular complications and mortality in type 2 diabetes patients: a meta-analysis. PLoS One 2013, 8(10):e78206.
45. Yamashita S., Matsuzawa Y., Tokunaga K., Fujioka S., Tarui S. Studies on the impaired metabolism of uric acid in obese subjects: marked reduction of renal urate excretion and its improvement by a low-calorie diet. Int. J. Obes. 1986, 10(4):255-264.
46. Yao J.K., Dougherty G.G., Reddy R.D., Matson W.R., Kaddurah-Daouk R., Keshavan M.S. Associations between purine metabolites and monoamine neurotransmitters in first-episode psychosis. Front. Cell. Neurosci. 2013, 7:90.